Why can't people get estradiol patches?
The FDA's explanation is that demand has risen faster than supply: particular brands and strengths run out at particular pharmacies while patches as a whole are still being shipped.[1] That is also why two lists disagree. The FDA has not declared a shortage and says patches “remain available”.[2] The pharmacists' society ASHP has listed a shortage since 30 January 2026 and now counts 24 of 46 packs as affected.[3]
Last updated: 20 November 2026. This page reports supply status and sources only. It is not medical advice.
| Where you look | What it shows on 20 Nov 2026 |
|---|---|
| FDA Drug Shortages database | 0 entries for estradiol, current or resolved[4] |
| Pharmacists' list (ASHP): packs listed as affected | 24 of 46[5] |
| Pharmacists' list (ASHP): packs listed as available | 22 of 46[6] |
| Companies with at least one affected pack | 5 of 6[7] |
A “pack” here is one brand, strength and pack size with its own product code. Counts are ours, from the ASHP bulletin dated 4 November 2026.[8]
What we know
- The FDA has not declared a shortage. Its database has no estradiol entry.[9] On 3 September it said that “availability of certain products or brands may vary by pharmacy or location”.[10] On 30 October the health department said the FDA “is not aware of an imminent risk of a nationwide shortage” and described “localized challenges”.[11]
- The pharmacists' list says otherwise. ASHP lists 24 packs from 5 companies as affected. All 22 packs it lists as available come from two companies: Mylan (Viatris) with 16 and Amneal with 6.[12]
- The stated cause is demand. The FDA says demand rose after it asked companies in November 2025 to remove boxed warnings from menopause hormone therapy labels.[13][14] A Sandoz spokesperson told Reuters in April that this “created unprecedented demand that cannot fully be met at present”.[15]
- Supply has grown, but factories are slow to expand. The FDA says supply “has nearly doubled” in a year, and that larger expansions take time because patches need specialised equipment.[16]
The ledger: product by product
One row per product line in the ASHP bulletin of 4 November 2026.[17] None of these products is on the FDA shortage list.[18] Strengths are the labelled release rates. The status terms (back order, on allocation) are ASHP's.
| Product | Listed as affected | Listed as available | Reason and expected date |
|---|---|---|---|
| Climara (Bayer) once-weekly | All 6 strengths | None | No reason given to ASHP. Intermittent back order; released as it becomes available. |
| Estradiol patch (Sandoz) once-weekly | All 6 strengths | None | No reason given to ASHP. 0.0375 mg/24 hour on back order with no date; the rest on allocation. |
| Estradiol patch (Mylan, a Viatris company) 4-count packs | None | All 6 strengths | Listed as available. |
| Dotti (Amneal) twice-weekly | 0.0375 mg/24 hour | 4 other strengths | No reason given to ASHP. Back order; the company cannot estimate a release date. |
| Lyllana (Amneal) twice-weekly | 0.025, 0.05 and 0.1 mg/24 hour | 0.0375 and 0.075 mg/24 hour | No reason given to ASHP. Back order with no date. |
| Estradiol patch (Noven, sold via Grove) twice-weekly | All 5 strengths | None | Increased demand. Intermittent back order, with weekly releases. |
| Estradiol patch (Zydus) twice-weekly | 0.05, 0.075 and 0.1 mg/24 hour | None listed | No reason given to ASHP. 0.05 and 0.1: back order, release estimated for early November 2026. 0.075: on allocation. |
| Estradiol patch (Mylan, a Viatris company) 8-count packs | None | All 10 packs (5 strengths) | Listed as available. |
FDA's Orange Book lists six companies with approved prescription estradiol-only patches: Amneal, Bayer, Mylan, Noven, Sandoz and Zydus.[19] The FDA says it is working with “all six manufacturers” but does not name them.[20] Three brands in the Orange Book are in neither ASHP list: Vivelle-Dot (Sandoz), Menostar (Bayer) and Minivelle (Noven).[21] ASHP says Minivelle was discontinued in February.[22]
How “no shortage” and “my pharmacy can't fill it” are both true
The two lists measure different things. This table quotes a comparison written jointly by the FDA, ASHP and the University of Utah, and the FDA's own FAQ.
| Question | FDA | ASHP |
|---|---|---|
| What counts as a shortage | “on a nationwide level, supply is not meeting current demand”[23] | Verified with manufacturers, and it “affects how pharmacy prepares or dispenses a product”[24] |
| Whose view it reflects | “shortage status at drug firm level”[25] | “status at healthcare provider level”[26] |
| When it ends | “One or more manufacturers are in production and able to meet full market demand”[27] | “All manufacturers of the drug restore all formulations and dosage sizes to full availability”[28] |
The FDA adds up all approved patches from all makers across the country. Its database says a market is covered when one manufacturer can meet total demand, and that even then “some manufacturers may not have all presentations available”.[29] ASHP lists a product while any maker has a gap in any strength, and notes that it “frequently lists more shortages than FDA”.[30] A prescription is for one product and one strength, which is the level ASHP tracks.
Where the records conflict
- Inside the ASHP bulletin. One section says “Lyllana is currently available”; another says three Lyllana strengths are on back order. It also refers to a shortage of Viatris twice-weekly patches while listing every Viatris pack as available.[31]
- How many products. A letter from eight members of Congress dated 31 July put ASHP's count at 14 “brands or dosages”.[32] The 4 November bulletin lists 24.[33] We could not read earlier versions, so the trend is unconfirmed.
- How much demand grew. No official figure exists. The letter cites Epic Research: prescriptions up 72% between 2021 and autumn 2025.[34] Reuters cites Truveta: use up 184% since 2023.[35] We did not read either dataset.
Outside the US: Australia's regulator lists a shortage of estradiol patches after notices from Sandoz and Juno. It calls the shortage “global” and expects four Estradot strengths back by 30 June 2027.[36]
What is still unknown
- The numbers behind the FDA's view. It has published no supply or demand figures for patches.
- Why four of the five affected companies have gaps. Only Noven gave ASHP a reason.[37]
- When it ends. No official source gives a date. Zydus's early-November estimate has not been confirmed.[38]
- Whether the FDA has answered Congress. The House letter asked seven questions.[39] A local news report says three senators asked on 20 October what it would take to list the patches, with answers due 16 November.[40] We found no published reply.
What would settle it
- FDA figures for patches shipped and prescriptions written, by month.
- The FDA's written answers to the two congressional letters.
- The next ASHP update, and any dated release notice from a manufacturer.
How this page was made
Every source was opened and read on 20 November 2026. Counts come from a script run over saved copies of the ASHP bulletin, the Orange Book product file and the FDA shortage download (1,579 rows, 224 drug names, none containing “estradiol”).[41][42] The FDA's public data service gave the same result. We found no supply statement on any manufacturer's own website; the company positions here are as reported to ASHP or Reuters. The senators' letter was read only in a news report.[43] Left out: pharmacy-level anecdotes, clinic blogs, survey results, and any guidance on treatment. Canadian and UK regulators were not checked. For questions about a prescription, the FDA points patients to their pharmacist or prescriber.[44]
Let's look at alternatives:
- Modify the query.
- Start a new thread.
- Remove sources (if manually added).